Abivax Unveils New Data on Obefazimod at ECCO 2026

Abivax has announced the acceptance of 22 abstracts focusing on obefazimod for inflammatory bowel disease (IBD) at ECCO 2026 in Stockholm. This includes a notable oral presentation on preclinical anti-fibrotic findings. Obefazimod's efficacy and safety were demonstrated across a variety of patient subpopulations in the Phase 3 ABTECT Induction Trials for ulcerative colitis (UC). The findings highlighted the drug's ability to downregulate pro-inflammatory cytokines and its favorable tolerability profile.

The preclinical study explored obefazimod's anti-fibrotic effects, particularly in Crohn's disease, addressing a significant unmet need. Scarring in the intestine can lead to strictures requiring surgery. The study assessed effects using both in vitro and in vivo models, with the presentation of these findings expected to be a significant highlight.